JP6348567B2 - マイクロエマルジョン局所送達プラットフォーム - Google Patents

マイクロエマルジョン局所送達プラットフォーム Download PDF

Info

Publication number
JP6348567B2
JP6348567B2 JP2016501962A JP2016501962A JP6348567B2 JP 6348567 B2 JP6348567 B2 JP 6348567B2 JP 2016501962 A JP2016501962 A JP 2016501962A JP 2016501962 A JP2016501962 A JP 2016501962A JP 6348567 B2 JP6348567 B2 JP 6348567B2
Authority
JP
Japan
Prior art keywords
oil
api
pharmaceutical composition
surfactants
eye
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016501962A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016512562A5 (cg-RX-API-DMAC7.html
JP2016512562A (ja
Inventor
エイ ワッセル，ロナルド
エイ ワッセル，ロナルド
ジョージ モンダレク，ファディー
ジョージ モンダレク，ファディー
エイ ファージョ，ラファル
エイ ファージョ，ラファル
ビー キャンバオ，アレクサンダー
ビー キャンバオ，アレクサンダー
ジェイ ヌーノ，ディディエ
ジェイ ヌーノ，ディディエ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eyecro LLC
Original Assignee
Eyecro LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eyecro LLC filed Critical Eyecro LLC
Publication of JP2016512562A publication Critical patent/JP2016512562A/ja
Publication of JP2016512562A5 publication Critical patent/JP2016512562A5/ja
Application granted granted Critical
Publication of JP6348567B2 publication Critical patent/JP6348567B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2016501962A 2013-03-14 2014-03-13 マイクロエマルジョン局所送達プラットフォーム Active JP6348567B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361784005P 2013-03-14 2013-03-14
US61/784,005 2013-03-14
PCT/US2014/025773 WO2014160079A1 (en) 2013-03-14 2014-03-13 Microemulsion topical delivery platform

Publications (3)

Publication Number Publication Date
JP2016512562A JP2016512562A (ja) 2016-04-28
JP2016512562A5 JP2016512562A5 (cg-RX-API-DMAC7.html) 2017-02-23
JP6348567B2 true JP6348567B2 (ja) 2018-06-27

Family

ID=50628949

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016501962A Active JP6348567B2 (ja) 2013-03-14 2014-03-13 マイクロエマルジョン局所送達プラットフォーム

Country Status (12)

Country Link
US (2) US8968775B2 (cg-RX-API-DMAC7.html)
EP (1) EP2968139B1 (cg-RX-API-DMAC7.html)
JP (1) JP6348567B2 (cg-RX-API-DMAC7.html)
CN (1) CN105451718B (cg-RX-API-DMAC7.html)
AU (1) AU2014244154B2 (cg-RX-API-DMAC7.html)
CA (1) CA2905023C (cg-RX-API-DMAC7.html)
DK (1) DK2968139T3 (cg-RX-API-DMAC7.html)
ES (1) ES2673009T3 (cg-RX-API-DMAC7.html)
PL (1) PL2968139T3 (cg-RX-API-DMAC7.html)
PT (1) PT2968139T (cg-RX-API-DMAC7.html)
TR (1) TR201808197T4 (cg-RX-API-DMAC7.html)
WO (1) WO2014160079A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009000486A (es) 2006-07-13 2009-01-27 Achillion Pharmaceuticals Inc Peptidos de 4-amino-4-oxobutanoilo como inhibidores de replicacion viral.
ES2584534B1 (es) * 2015-03-27 2017-03-13 Retinset, S.L. Formulación tópica oftálmica de bosentan
AU2017208970A1 (en) 2016-01-18 2018-08-02 Arisan Therapeutics Adamatane derivatives for the treatment of filovirus infection
EP3266446B1 (en) 2016-07-07 2018-11-21 Laboratorios SALVAT, S.A. Ophthalmic composition comprising castor oil and medium chain triglyceride
WO2019018185A1 (en) 2017-07-15 2019-01-24 Arisan Therapeutics Inc. ENANTIOMERICALLY PURE ADAMATANE DERIVATIVES FOR THE TREATMENT OF FILOVIRUS INFECTIONS
IL272601B2 (en) 2017-08-27 2025-03-01 Rhodes Tech Inc Pharmaceutical compositions for the treatment of ophthalmic conditions
US11583497B2 (en) 2017-11-14 2023-02-21 The Schepens Eye Research Institute, Inc. Nano-emulsion of CBFß-RUNX1 inhibitor for ocular drug delivery
EP3982930A1 (en) 2019-06-11 2022-04-20 SIFI S.p.A. Microemulsion compositions
WO2021005676A1 (ja) * 2019-07-08 2021-01-14 株式会社Moresco マイクロエマルションを調製するための組成物、マイクロエマルション、これらの製造方法、及びマイクロエマルションの利用
US20240415796A1 (en) * 2020-11-19 2024-12-19 Nihon University Eyedrops for ameliorating or preventing retinal circulation disorder and retinal neurovascular coupling disorder
WO2025034554A1 (en) * 2023-08-04 2025-02-13 Ads Therapeutics Llc Compositions and methods for delivery of ophthalmological actives
WO2025090133A1 (en) 2023-10-23 2025-05-01 Inmed Pharmaceuticals Inc. Compositions and methods for use of cannabinol compounds in neuroprotection

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI398261B (zh) * 2003-12-17 2013-06-11 Alcon Inc 血清類澱粉ａ基因於診斷及治療青光眼及鑑定抗青光眼劑上之用途
US7569612B1 (en) * 2006-08-21 2009-08-04 Mutual Pharmaceutical Company, Inc. Methods of use of fenofibric acid
US20090082470A1 (en) * 2007-09-24 2009-03-26 Rafal Farjo Stat3 inhibiting compositions and methods
US8652443B2 (en) * 2008-02-14 2014-02-18 Precision Dermatology, Inc. Foamable microemulsion compositions for topical administration
JP2014508749A (ja) * 2011-02-11 2014-04-10 サイヴィーダ ユーエス，インコーポレイテッド 抗浮腫治療薬を使用する黄斑浮腫の治療方法
WO2013049621A1 (en) * 2011-09-29 2013-04-04 The Board Of Regents Of The University Of Oklahoma Ophthalmic compositions comprising ppar-alpha agonists and methods of production and use thereof

Also Published As

Publication number Publication date
TR201808197T4 (tr) 2018-07-23
US20140275263A1 (en) 2014-09-18
EP2968139A1 (en) 2016-01-20
DK2968139T3 (en) 2018-06-25
EP2968139B1 (en) 2018-05-23
CN105451718A (zh) 2016-03-30
US8968775B2 (en) 2015-03-03
CN105451718B (zh) 2018-09-28
PT2968139T (pt) 2018-06-18
WO2014160079A1 (en) 2014-10-02
CA2905023C (en) 2019-10-15
CA2905023A1 (en) 2014-10-02
US20150164846A1 (en) 2015-06-18
AU2014244154B2 (en) 2018-08-09
AU2014244154A1 (en) 2015-09-24
ES2673009T3 (es) 2018-06-19
PL2968139T3 (pl) 2018-10-31
US9149453B2 (en) 2015-10-06
JP2016512562A (ja) 2016-04-28

Similar Documents

Publication Publication Date Title
JP6348567B2 (ja) マイクロエマルジョン局所送達プラットフォーム
JP2016512562A5 (cg-RX-API-DMAC7.html)
JP7547411B2 (ja) 局所用シクロスポリン含有製剤およびその使用
JP7496778B2 (ja) チモロールを含む医薬組成物
JP7353292B2 (ja) ネビボロールを含む医薬組成物
US20210085603A1 (en) Microemulsion for opthalmic drug delivery
JP2017519813A (ja) 局所製剤およびその使用
JP7669326B2 (ja) 局所製剤およびその使用
KR20150000405A (ko) 난용성 의약품의 수중유적형 에멀젼 조성물 및 이의 제조방법
JP2018532809A5 (cg-RX-API-DMAC7.html)
CN116898800A (zh) 无防腐剂的眼科药物乳剂及其应用
KR101151235B1 (ko) 나노에멀젼 형태의 안과용 조성물
US20140302099A1 (en) Ophthalmic Composition Containing Cyclosporine And method For Preparing Same
Acharya Development and Evaluation of Liquid Crystalline Cubogel for Ocular Delivery of Anti-glaucoma Agents
HK40044057A (en) Pharmaceutical compositions comprising nebivolol
Khodakiya Formulation Design and Optimization of topical Microemulsion in Situ Gelling System: Drug Delivery to Posterior Segment of the Eye
HK40044057B (zh) 包含奈必洛尔的药物组合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170113

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170113

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171017

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180116

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180508

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180531

R150 Certificate of patent or registration of utility model

Ref document number: 6348567

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250